Prevalence of PRISm and COPD and associated factors in a university medical centre spirometry unit: a cross-sectional analysis Authors: Zeina Akiki, Emilio Khoueiry, Elissa Smayra, Antonio Nader, Karen El Teress, Caren Safi, Imad El Ashkar, Ali Majed, Ali Fawaz, Pascale Salameh, Dany Gaspard Published: 2026 ABSTRACT Abstract AbstractObjectivesPreserved Ratio Impaired Spirometry (PRISm) is a new spirometric entity defined in international guidelines, associated with overall worse outcomes. It remains unclear whether this represents a distinct entity or an early phase of multiple other diseases, such as chronic obstructive pulmonary disease (COPD) and restrictive lung diseases. There is a notable scarcity of data on PRISm, particularly in Lebanon. This study aimed to evaluate the prevalence of PRISm and COPD, and their associated factors, among individuals aged 40 years and above who underwent spirometry in a single university medical centre between 2022 and 2024.SettingOutpatient Pulmonary Function Tests Laboratory at a Lebanese university medical centre.ParticipantsAll individuals aged 40 years or older who performed spirometry between 2022 and 2024MethodsA retrospective analysis of pulmonary function tests (PFTs) and demographics was performed. Patients were classified based on the spirometry patterns that are consistent with COPD (forced expiratory volume in the first second (FEV1)/forced vital capacity (FVC)<0.7 post bronchodilator), PRISm (FEV1/FVC≥0.7 and FEV1<80% post bronchodilator) and normal PFTs (FEV1/FVC≥0.7 and FEV1≥80%). A small number of PFTs did not meet the above criteria and were classified as ‘others’; they were excluded from the main analysis but retained for descriptive estimation of PRISm and COPD prevalence over the past 3 years. The prevalence and associated risk factors of PRISm and COPD were assessed. Descriptive, bivariate and multinomial regression models were performed using IBM’s Statistical Package for the Social Sciences V.29.ResultsA total of 698 PFTs were performed for 639 patients. The prevalence of PRISm and COPD in the centre between 2022 and 2024 was 11% and 17%, respectively. Compared with normal PFTs, subjects with PRISm were older (adjusted OR; aOR (95% CI)=1.03 (1.002 to 1.05); p=0.03) and more likely to be ex-smokers (aOR=2.19 (1.12 to 4.30); p=0.022); patients with COPD were older (aOR 1.09 (1.07 to 1.12); p<0.001), had lower body mass index (aOR 0.95 (0.91 to 0.99); p=0.024) and were more likely to be smokers or ex-smokers.ConclusionThese findings highlight PRISm as a potentially relevant pattern within chronic airway disease. Within the context of Sustainable Development Goal 3 on non-communicable diseases, they underscore the importance of identifying this subgroup for closer clinical attention. Further longitudinal and multicentre studies are needed to better understand the clinical significance of PRISm and its relationship to chronic airway diseases.Keywords: Prevalence; Pulmonary Disease, Chronic Obstructive; Respiratory Function Test STRENGTHS AND LIMITATIONS OF THIS STUDY Large number of pulmonary function tests collected over a 3-year period at a referral university medical centre. Large number of pulmonary function tests collected over a 3-year period at a referral university medical centre. Analysis based on standardised spirometry following Global Initiative for Chronic Obstructive Lung Disease guidelines. Analysis based on standardised spirometry following Global Initiative for Chronic Obstructive Lung Disease guidelines. Cross-sectional design allows for assessment of associations but not causality. Cross-sectional design allows for assessment of associations but not causality. The single-centre setting may limit generalisability of findings. The single-centre setting may limit generalisability of findings. Final diagnosis of respiratory diseases may require additional assessments beyond spirometry, including functional testing and chest imaging. Final diagnosis of respiratory diseases may require additional assessments beyond spirometry, including functional testing and chest imaging. Introduction Chronic respiratory diseases, including early airflow limitations and restrictive patterns, represent a growing global health concern and are directly linked to the Sustainable Development Goal (SDG) 3, which emphasises reducing premature mortality from non-communicable diseases (NCDs) by one-third by 2030.1 Chronic obstructive pulmonary disease (COPD) is one of the most prevalent respiratory diseases.2 It is a heterogeneous lung condition characterised by chronic respiratory symptoms resulting from the airways and/or alveolar abnormalities, leading to persistent and often progressively worsening airflow obstruction.3 COPD is one of the top three causes of death worldwide, with 3.23 million deaths in 2019 and 90% of deaths under 70 years of age occurring in low-income to middle-income countries (LMICs).2 4 5 The global burden is expected to increase by 23% between 2020 and 2050, reaching an estimated 600 million cases worldwide.6 COPD diagnosis is suspected based on clinical symptoms and confirmed by spirometry with the presence of non-fully reversible airflow limitation (forced expiratory volume in the first second (FEV1)/forced vital capacity (FVC)<0.7 post bronchodilation). Risk factors for COPD include being 40 years of age or older, smoking, exposure to secondhand smoke, ambient air pollution, indoor biomass burning, occupational dust exposure and childhood asthma.3 7 Recent studies described the Preserved Ratio Impaired Spirometry (PRISm) as a distinct spirometry pattern of chronic respiratory diseases, defined by a reduced FEV1 despite a preserved ratio of FEV1 to FVC. A 2024 systematic review reported a pooled PRISm prevalence of 12% (95% CI 0.10 to 0.15).8 Risk factors include older age, being a smoker, being obese or underweight, asthma history and a low socioeconomic status.9,11 Moreover, PRISm is associated with increased respiratory symptoms as well as higher all-cause, respiratory and cardiovascular mortality.10,14 While the association between COPD and PRISm remains relatively underexplored, recent literature suggests potential links. Both share pathophysiological similarities, such as small airway disease and air trapping,15 16 as well as common risk factors, such as smoking and environmental exposures.7 10 11 Additionally, PRISm might represent a transitional phase with individuals either progressing to COPD or reverting to normal lung function.10 12 In a follow-up study with a duration of 5–9 years, 26.7% of individuals with PRISm returned to normal spirometry and 19.8% progressed to COPD.17 In Lebanon, a low-income country from the Middle East, COPD prevalence was reported to be 9.7% in 2011.18 Additionally, the country has long shown high levels of COPD risk factors, with cigarette smoking prevalent in 48.6% of men and 21.5% of women and waterpipe smoking reported in 32.7% of men and 46.2% of women.19 Moreover, Lebanon faces significant air pollution challenges, especially in urban areas, driven by industrial emissions, electricity generators and traffic congestion.20 21 These exposures may contribute to reduced lung function and a higher likelihood of abnormal spirometry patterns. Therefore, assessing the prevalence of PRISm and tracking COPD trends is particularly important in Lebanon, given the high exposure to risk factors such as cigarette and waterpipe smoking and severe urban air pollution.18,21 As our understanding of PRISm progresses and as we try to assess its associations and eventual progression, data for Lebanon is particularly important given its economic crisis, weakening healthcare system and ongoing healthcare professionals’ migration. Should PRISm be established as a precursor state of COPD, detecting it early can help slow progression and ease the burden on strained health services. Moreover, a 2024 systematic review emphasised the need for additional studies in LMICs to better understand unique exposures and disease trajectories.8 Strengthening knowledge in this area will support more tailored care and improve outcomes for vulnerable populations. To our knowledge, this is the first study to evaluate PRISm in the Lebanese population. The objective was to determine the prevalence of PRISm and COPD and identify associated risk factors among individuals aged 40 years and older who underwent spirometry at the Lebanese American University Medical Center-Rizk Hospital (LAUMC-RH) between 2022 and 2024, following the adoption of the Global Lung Function Initiative reference equations. Identifying PRISm may help detect individuals at higher risk who could benefit from closer monitoring and preventive strategies. Methods Study design and participants A retrospective analysis of the pulmonary function tests (PFTs) results of all patients aged over 40 years who underwent spirometry tests at LAUMC-RH between January 2022 and December 2024 was conducted. Selecting 40 years as the lower cut-off age was intended to reduce the probability of asthma, which is more prevalent in a younger populations. Patient and public involvement Given the study’s characteristics, patients or the public were not involved in the design or conduct of this study. Patients’ records The patients’ records included the following variables: PFT results, mainly FEV1, FEV1 % predicted, FVC, FVC % predicted, FEV1/FVC, pre and post bronchodilator, year of birth, sex, height (in cm), weight (in kg) and smoking status (smokers, ex-smokers or non-smokers). The PFTs were classified according to the 2025 Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines3 as: Normal PFT (FEV1/FVC≥0.7 and FEV1≥80%). Normal PFT (FEV1/FVC≥0.7 and FEV1≥80%). PRISm (FEV1/FVC≥0.7 post bronchodilator and FEV1<80% post bronchodilator). PRISm (FEV1/FVC≥0.7 post bronchodilator and FEV1<80% post bronchodilator). COPD (FEV1/FVC<0.7 post bronchodilator). COPD (FEV1/FVC<0.7 post bronchodilator). A small number of PFTs did not fit any of the above criteria (examples include a low prebronchodilator FEV1/FVC that normalises post bronchodilator or a normal postbronchodilator FEV1/FVC with normal FEV1 and low FVC, etc). These PFTs were classified as ‘others’ and excluded from the main analysis but retained for descriptive estimation of PRISm and COPD prevalence over the past 3 years. A small number of PFTs did not fit any of the above criteria (examples include a low prebronchodilator FEV1/FVC that normalises post bronchodilator or a normal postbronchodilator FEV1/FVC with normal FEV1 and low FVC, etc). These PFTs were classified as ‘others’ and excluded from the main analysis but retained for descriptive estimation of PRISm and COPD prevalence over the past 3 years. We note that the extent of bronchodilator response per se was not used as a diagnostic criterion, as it is now recognised to have little value in differentiating asthma from COPD.3 Sample size calculation Although this was a retrospective analysis of PFT results, a sample size calculation was conducted to assess whether the available 3-year dataset would be sufficient to provide a precise estimate of PRISm prevalence. This calculation was not used to determine the observed prevalence, which was derived directly from all eligible spirometry records, but rather to evaluate the adequacy of the dataset size in relation to standard precision criteria. Center for Disease control and prevention Epi Info V.7.2.4 was used for sample size calculation. The expected prevalence of PRISm was based on prior hospital-based studies reporting rates of 22.3% and 17.7% for prebronchodilator and postbronchodilator spirometry, and 20.7% and 24.3% among unique subjects.22 The highest reported prevalence (24.3%) was used to provide a conservative estimate. Assuming a 95% confidence level and a 5% margin of error, a minimum of 283 participants was required. Statistical analysis Descriptive statistics were performed to represent the patients’ characteristics and were expressed as mean±SD for continuous variables and percentages for qualitative variables. The prevalence of PRISm in postbronchodilator spirometry tests and among unique subjects, as well as the prevalence of COPD among participants aged 40 years or above and who performed spirometry at LAURMC-RH during the past 3 years, from 2022 to 2024, were assessed. The variable comprising ‘PRISm, COPD, normal PFT’ was computed. A descriptive analysis was conducted to describe the participants’ characteristics, followed by a bivariate analysis between ‘PRISm, COPD versus normal PFTs’ and the participants’ characteristics. The Analysis of Variance (ANOVA) test was applied for comparisons involving three or more groups (age or body mass index (BMI)), after verifying homogeneity of variances using Levene’s test. When the assumption of homogeneity was violated, the Welch’s ANOVA test was used instead. Additionally, the χ2 or Fisher exact tests were applied to test the associations between the PFT classification (COPD, PRISm, normal PFT) and gender and smoking status as appropriate. Because the dependent variable had three mutually exclusive categories, PRISm, COPD and normal PFTs, a multivariable analysis using a multinomial logistic regression was used with age, gender, BMI and smoking status as covariates. This approach allowed simultaneous comparison of each non-reference category against normal PFTs while adjusting for predictors (age, gender, BMI, smoking status), avoiding multiple separate binary models and reducing the risk of inflated type 1 error. An alpha of 0.05 was used to determine statistical significance. All analyses were performed using IBM’s Statistical Package for the Social Sciences V.29.0. Results COPD and PRISm prevalence in the hospital setting A total of 698 PFTs were performed in patients aged 40 years or above at LAUMC-RH between 2022 and 2024 (table 1), corresponding to 639 unique patients. A flowchart (figure 1) represents the screening process and the classification of participants into normal PFTs, PRISm and COPD. Based on all 698 PFTs, COPD prevalence was 18% and 10% of tests were consistent with PRISm. When considering only unique patients (n=639), the prevalence of COPD and PRISm based on baseline spirometry was 17% and 11%, respectively. Table 1Distribution of PFT results by year (n=698)PFT resultsn=6982022182 (26%)2023243 (35%)2024273 (39%)PFT, pulmonary function test. Distribution of PFT results by year (n=698) PFT, pulmonary function test. Flowchart for the screening process and the classification of participants. COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in the first second; FVC, forced vital capacity; PFT, pulmonary function test; PRISm, Preserved Ratio Impaired Spirometry. Bivariate analysis for the predictors associated with different spirometry patterns After excluding the 43 patients classified as others, the bivariate analysis showed that participants with COPD were significantly older (mean±SD=71±8 years; p<0.001), and PRISm participants had a significantly higher BMI (mean±SD=29.7±7 kg/m2; p=0.002). Participants with COPD were more likely to be smokers, while PRISm participants were more likely to be ex-smokers (p<0.001). No other significant associations were observed (table 2). Table 2Bivariate association between PFT results from the baseline spirometry and patients’ characteristicsCOPD(n=111)PRISm(n=68)Normal PFTs (n=417)P valueAge; mean±SD71±865±961±13 <0.001 Min–Max45–9042–8540–96BMI; mean±SD26.7±529.7±728.3±5 0.002 Min–Max15.8–52.117.3–48.415.6–47Gender; n (%)0.829Male55 (50%)34 (50%)196 (47%)Female56 (50%)34 (50%)221 (53%)Smoking status; n (%) <0.001 Non-smokers17 (15%)20 (30%)144 (35%)Smokers65 (59%)24 (35%)196 (48%)Ex-smokers28 (26%)24 (35%)73 (18%)Statistically significant values are highlighted in bold.Age: p value (normal PFTs and COPD)<0.001; p value (PRISm and COPD)=0.003; p value (PRISm and normal) = 0.02; BMI: p value (COPD and PRISm=0.001); p value (COPD and normal PFT=0.023).BMI, body mass index; COPD, chronic obstructive pulmonary disease; Max, maximum; Min, minimum; PFT, pulmonary function test; PRISm, Preserved Ratio Impaired Spirometry. Bivariate association between PFT results from the baseline spirometry and patients’ characteristics Statistically significant values are highlighted in bold. Age: p value (normal PFTs and COPD)<0.001; p value (PRISm and COPD)=0.003; p value (PRISm and normal) = 0.02; BMI: p value (COPD and PRISm=0.001); p value (COPD and normal PFT=0.023). BMI, body mass index; COPD, chronic obstructive pulmonary disease; Max, maximum; Min, minimum; PFT, pulmonary function test; PRISm, Preserved Ratio Impaired Spirometry. Multivariable analysis for the factors associated with different spirometry patterns Multivariable analysis showed that participants with COPD were significantly older (aOR (95% CI)=1.09 (1.07 to 1.12); p<0.001), had a lower BMI (0.95 (0.91 to 0.99); p=0.024) and were more likely to be smokers (3.92 (2.09 to 7.34)) or ex-smokers (2.75 (1.35 to 5.60); p=0.005) compared with participants with normal PFT results. PRISm participants were significantly older (1.03 (1.002 to 1.05); p=0.03) and were more likely to be ex-smokers (2.19 (1.12 to 4.30); p=0.022). No other significant associations were observed (table 3). Table 3Multinomial logistic regression for factors associated with COPD, PRISm and other PFT results compared with normal PFTsAdjusted OR (95% CI)P valueCOPDAge1.09 (1.07 to 1.12) <0.001 BMI0.95 (0.91 to 0.99) 0.024 Gender, male0.80 (0.50 to 1.27)0.342Smoking statusNon-smokersReferenceSmokers3.92 (2.09 to 7.34) <0.001 Ex-smokers2.75 (1.35 to 5.60) 0.005 PRISmAge1.03 (1.002 to 1.05) 0.030 BMI1.04 (1.00 to 1.09)0.070Gender, male0.94 (0.55 to 1.60)0.820Smoking statusNon-smokersReferenceSmokers1.00 (0.53 to 1.90)0.999Ex-smokers2.19 (1.12 to 4.30) 0.022 Statistically significant values are highlighted in boldBMI, body mass index; COPD, chronic obstructive pulmonary disease; PFT, pulmonary function test; PRISm, Preserved Ratio Impaired Spirometry. Multinomial logistic regression for factors associated with COPD, PRISm and other PFT results compared with normal PFTs Statistically significant values are highlighted in bold BMI, body mass index; COPD, chronic obstructive pulmonary disease; PFT, pulmonary function test; PRISm, Preserved Ratio Impaired Spirometry. Discussion This study is the first to assess PRISm and its associated factors within the Lebanese population. In a hospital-based setting, where testing was predominantly performed on outpatients, the prevalence of COPD and PRISm was found to be 17% and 11%, respectively. COPD was significantly associated with older age, lower BMI and a history of smoking (current or former), whereas PRISm was significantly associated with older age and a history of former smoking. PRISm prevalence This study identified a baseline PRISm prevalence of 11% among outpatient individuals aged 40 years or above, aligning with international community-based studies, reporting prevalence rates between 7% and 11% among adult populations.11 13 23 On one hand, studies conducted among the general population aged 40 and above, using the fixed ratio definition, reported baseline PRISm prevalence of 5% and 8.2%, respectively,17 24 while on the other hand, a study conducted in a tertiary referral centre in the USA, but using the lower limits of normal (LLN) criteria definition reported a postbronchodilation PRISm prevalence of 17.7%.22 We believe that the relatively higher PRISm prevalence observed in this study, compared with community-based studies such as those by Perez-Padilla et al and Fan et al,17 24 is attributable to the study population, which consisted of outpatients undergoing pulmonary function testing, likely representing individuals with greater respiratory symptoms or risk factors. However, the prevalence remains lower than that reported by Schwartz et al in a hospital-based setting,22 which may be explained by differences in diagnostic criteria and a higher proportion of active smokers in their study population. Additionally, studies involving populations with heavier smoking exposure, such as the COPDGene cohort study, which included participants with a minimum of 10 pack-years of smoking history, have reported a PRISm prevalence of 12.3%, consistent with the well-established association between tobacco and lung function impairment.9 It should be noted that the slight difference in prevalence observed in the present study, when compared with lower or higher figures in other settings, may be attributed to differences in age distribution, smoking status, comorbidity profiles, ethnicity, clinical context and the diagnostic criteria applied. Overall, this study’s findings emphasise the importance of assessing PRISm in routine respiratory evaluation. Furthermore, incorporating spirometry into standard care practices aligns with SDG 3 goal, particularly Target 3.4, which seeks to reduce premature mortality from NCDs through prevention and treatment. PRISm associated factors In this study, older age was significantly and positively associated with PRISm, which is consistent with previous literature.22 23 In fact, age-related changes in lung function include a loss of lung elasticity, increased gas trapping, and enlargement of distal air spaces.25 These normal ageing processes decrease lung capacity and weaken the respiratory muscles, eventually contributing to chronic respiratory conditions. Concerning smoking, this study found an association between PRISm and former smoking, consistent with a 2025 meta-analysis. This may reflect persistent structural or functional airway damage after smoking cessation, as smoking-related small airway disease may persist even after cessation, leading to persistent low FEV₁ despite preserved FEV₁/FVC.26 No association was found with current smoking, in line with Siddharthan et al, who similarly reported no association in LMICs.27 This may be explained by earlier disease stages among current smokers or a potential healthy smoker bias, where more symptomatic individuals may have already quit. However, interpretation is limited by the lack of detailed smoking data (eg, pack-years or duration). Additionally, other environmental exposures, particularly biomass fuel use and air pollution, may have a stronger influence in this setting.20 21 The association between PRISm and BMI remains inconclusive. While our study found no significant association, previous studies have reported conflicting results, with some showing higher BMI associated with PRISm28 and others linking lower BMI to reduced lung function29 or finding no association at all.27 Overall, these discrepancies suggest a complex relationship that may vary by population and setting. No association between gender and PRISm was found in this study. Previous literature reported conflicting results regarding gender and PRISm, where some studies found higher prevalence in females,17 27 others in males23 and some showed non-significant trends toward higher rates in females.30 Overall, gender alone may not be a strong determinant of PRISm when other factors, such as age and smoking history, are accounted for. COPD prevalence This study reported a COPD prevalence of 17% in hospital settings, reflecting an increase compared with the national prevalence of 9.7% among 40 years old or above reported in 2011.18 This increase reflects the more symptomatic and comorbid population typically seen in hospital-based studies, alongside the growing exposure to COPD risk factors in Lebanon such as air pollution, smoking and secondhand smoking.19,21 COPD prevalence varies significantly across regions, largely influenced by differences in study design, diagnostic criteria and the populations studied. Moreover, COPD is frequently underdiagnosed, often due to under-recognition of symptoms, lack of spirometry use and overlap with other respiratory conditions.3 A 2022 systematic review estimated the global prevalence of COPD among people aged 30–79 years to be 10.3% (95% CI 8.2% to 12.8%) using the GOLD case definition and 7.6% (5.8% to 10.1%) using the LLN definition.31 These findings collectively underscore the need for expanded spirometry screening and earlier diagnosis, especially in primary care and underserved settings in Lebanon. COPD associated factors Older age emerged as a factor significantly and positively associated with COPD. This finding is consistent with findings from the previous literature3 32 and underscores the progressive nature of COPD and the need for early risk stratification, particularly in older individuals with known exposures. Interestingly, lower BMI was significantly associated with COPD, consistent with findings from a study conducted across 14 LMICs.29 Lower BMI has also been associated with more severe airflow limitation and increased exacerbation frequency.33 These findings highlight the importance of nutritional assessment and intervention in COPD management, as addressing weight loss and muscle wasting through nutritional support and pulmonary rehabilitation may improve outcomes and quality of life. The study reinforces the established association between smoking and COPD, with smokers and ex-smokers being more frequently affected. A large Korean cohort similarly showed that smoking significantly increases COPD risk even in young adults, with greater lung function decline with higher smoking intensity.34 Importantly, experimental evidence also suggests that smoking-induced lung damage and inflammation may persist even after cessation due to lasting molecular changes.35 Overall, while smoking cessation is essential, it may not fully reverse established damage, underscoring the importance of prevention and early intervention. Strengths and limitations This study offers several important strengths that enhance both its scientific value and clinical relevance. Most notably, it is the first investigation in Lebanon to explore PRISm, its prevalence and associated factors, making it a pioneering effort in the region. Moreover, it highlights trends in COPD prevalence, thus holding potential for long-term impact. Subsequently, by identifying at-risk groups and early abnormalities in lung function, this study lays the groundwork for future longitudinal research. It opens the door for better tracking of respiratory outcomes over time and may ultimately help formulate preventive strategies in similar populations. Several limitations should be acknowledged. First, it is important to note that this study is based solely on spirometry. Establishing a clinical diagnosis typically requires a comprehensive assessment, including clinical evaluation, advanced functional tests and chest imaging. PFTs are often performed when patients are in a stable state, so many individuals with asthma, for example, may have normal results at the time of testing. Second, the study was conducted at a single centre, which may limit the generalisability of the findings to patients from other institutions. Nonetheless, it is worth noting that the university medical centre where data were collected is based in the capital and serves patients from various Lebanese governorates. Additionally, environmental exposures, healthcare access and genetic variability across populations may affect the generalisability of our results. Third, the cross-sectional design of the study limits the interpretation of causal relationships between the variables studied. Fourth, although patients under 40 years were excluded by design to focus on age groups with higher expected prevalence of chronic lung impairment, this criterion may have limited our ability to capture early or atypical presentations of PRISm. The choice was made to enhance homogeneity and decrease the proportion of asthma patients, but future studies could consider including younger individuals to assess early-onset forms more directly. Fifth, despite adjustment for key covariates, the potential for residual confounding remains, particularly from unmeasured factors such as respiratory symptoms or detailed smoking history that were not available in the medical records. It is worth noting that a supplementary survey was initiated to collect additional data, including detailed smoking history, respiratory symptoms and quality of life measures. However, due to a low response rate (8%), the results were not included in this paper. Finally, future studies with larger cohorts and regular follow-up testing would be better positioned to capture these dynamic changes. Conclusion This study assessed the prevalence of PRISm and COPD at a single university medical centre as well as their associated factors. Participants with PRISm appear to be older, had lower BMI and were more likely to be ex-smokers, while patients with COPD appear to be older, had lower BMI and were more likely to be smokers or ex-smokers. These findings contribute to the growing evidence that PRISm may represent a clinically relevant stage in chronic airway diseases. Thus, recognising it as part of the spectrum of chronic respiratory conditions supports efforts toward achieving SDG 3 by promoting early intervention and improved long-term respiratory health outcomes. Future longitudinal and multicentre studies are warranted to validate these findings and to better define the natural trajectory and therapeutic needs of individuals with PRISm. Acknowledgements The authors thank the pulmonary physicians at the Lebanese American University Medical Center for providing access to patient records. Footnotes Funding: The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors. Prepublication history for this paper is available online. To view these files, please visit the journal online (https://doi.org/10.1136/bmjopen-2025-115602). Data availability free text: The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request. Patient consent for publication: Not applicable. Provenance and peer review: Not commissioned; externally peer reviewed. Patient and public involvement: Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research. Ethics approval: The study was approved by the institutional review board (IRB) at LAU (LAU.SOM.ZA4.30/Aug/2024). Data availability statement Data are available upon reasonable request. References Data Availability Statement Data are available upon reasonable request.